35 results about "Programmed death 1" patented technology

The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1), a Lymphocyte-Activation Gene 3 (LAG3) antagonist, and all-trans retinoic acid or a pharmaceutically acceptable salt thereof and the use of the combination therapies for the treatment of cancer.

The present disclosure provides methods for treating, reducing the severity of, inhibiting the growth of a tumor, or inducing necrosis of a tumor, wherein the method includes selecting a patient with cancer (e.g., liver cancer, lung cancer, or head and neck cancer) in need thereof and administering to the patient a neoadjuvant therapy comprising a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor (e.g., cemiplimab or a bioequivalent thereof) in combination with radiation therapy (e.g., SBRT) or an anti-LAG-3 antibody (e.g., fianlimab) followed by surgical resection, and optional administration of a programmed death 1 (PD-1) inhibitor (e.g., cemiplimab or a bioequivalent thereof) as post-surgery adjuvant therapy. In certain embodiments, the cancer is liver cancer, such as hepatocellular carcinoma (HCC).

The present disclosure provides methods for treating, reducing the severity of, inhibiting the growth of a tumor, or inducing necrosis of a tumor, wherein the method includes selecting a patient with cancer (e.g., liver cancer, lung cancer, or head and neck cancer) in need thereof and administering to the patient a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor (e.g., cemiplimab or abioequivalent thereof) as neoadjuvant therapy followed by surgical resection and optional administration of a programmed death 1 (PD-1) inhibitor (e.g., cemiplimab or a bioequivalent thereof) as post-surgery adjuvant therapy. In certain embodiments, the liver cancer is hepatocellular carcinoma (HCC), the lung cancer is non-small cell lung cancer (NSCLC), or the head and neck cancer is head and neck squamous cell carcinoma (HNSCC).

The present disclosure provides methods for treating or inhibiting the growth of a tumor, including selecting a patient with cancer, wherein the patient is immunosuppressed or immunocompromised, and administering to the patient a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor (e.g., an anti-PD-1 antibody, such as cemiplimab or a bioequivalent thereof). In certain embodiments, the cancer is skin cancer, such as cutaneous squamous cell carcinoma.

This disclosure provides methods for treating tumors, reducing tumor severity, inhibiting tumor growth, or inducing tumor necrosis, wherein the methods include: selecting a patient with cancer (e.g., liver cancer, lung cancer, or head and neck cancer) in need of treatment and administering neoadjuvant therapy to the patient in a combination of a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor (e.g., cimiprimab or its bioequivalent) and radiation therapy (e.g., SBRT) or an anti-LAG-3 antibody (e.g., fenpromab), followed by surgical resection and optionally administration of a programmed death 1 (PD-1) inhibitor (e.g., cimiprimab or its bioequivalent) as postoperative adjuvant therapy. In some embodiments, the cancer is liver cancer, such as hepatocellular carcinoma (HCC).

This disclosure provides methods for treating endometrial cancer, reducing its severity, or inhibiting its growth. The methods of this disclosure comprise administering to a subject in need a single therapeutically effective amount of a bispecific antibody that specifically binds to mucin 16 (MUC16) and CD3, or administering said bispecific antibody in combination with a therapeutically effective amount of an antibody specifically binding to the programmed death 1 (PD-1) receptor or an antigen-binding fragment thereof.

Provided herein are recombinant antibodies, antigen-binding fragments, and fusion proteins thereof useful for binding to and inhibiting programmed death 1 (PD-1), nucleic acid molecules encoding the same and therapeutic compositions thereof, as well as methods of using such antibodies, including the methods for enhancing T cell and NK cell function to increase cell and cytokine mediated immunity and methods of treatment of various immune dysfunction related disorders including cancer and infectious diseases.

The present disclosure provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., prostate cancer or metastatic castration-resistant prostate cancer). The methods of the present disclosure comprise administering to a subject in need thereof a therapeutically effective amount of a bispecific antibody, or antigen-binding fragment thereof, that specifically binds prostate specific membrane antigen (PSMA) and CD3, either alone or in combination with an antibody, or antigen-binding fragment thereof, that specifically binds to programmed death 1 (PD-1) receptor.

To provide a pharmaceutical composition for use in a method of treating lung cancer.SOLUTION: Provided is a pharmaceutical composition for use in a method of treating lung cancer or increasing the survival of a patient with lung cancer, the pharmaceutical composition comprising an isolated antibody or an antigen-binding fragment thereof that binds specifically to programmed death 1 (PD-1), the method comprising: (a) selecting a patient having non-small cell lung cancer; (b) measuring expression of programmed death ligand 1 (PD-L1) in lung cancer tumor tissue of the patient; and (c) if the tumor tissue in the patient expresses PD-L1 in ≥50% of tumor cells, administering one or more doses of a therapeutically effective amount of the antibody or the antigen-binding fragment thereof to the patient, thereby treating lung cancer in the patient.SELECTED DRAWING: None

The present disclosure provides methods for treating or inhibiting the growth of a tumor, wherein the method includes selecting a patient with lung cancer and brain metastasis in need thereof and administering to the patient a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor (e.g., cemiplimab or a bioequivalent thereof). In certain embodiments, the lung cancer is non-small cell lung cancer (NSCLC) and PD-L1 is expressed in ≥50% of tumor cells. In certain embodiments, the methods lead to improvements in functioning and quality of life.

Disclosed herein are recombinant antibodies specific to programmed death 1 (PD-1), chimeric antigen receptors (CARs) and genetically modified cells configured to express the CARs on their surfaces and secret the recombinant antibodies specific to PD-1. Also disclosed herein is a method of treating cancer by administering the genetically modified cells to a subject afflicted with cancer.

The present invention provides methods for treating, reducing the severity of, or inhibiting the growth of cancer (e.g., recurrent ovarian cancer). The methods of the invention comprise administering to a subject in need thereof a therapeutically effective amount of a bispecific antibody that specifically binds mucin 16 (MUC16) and CD3, alone or in combination with a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds programmed death 1 (PD-1).

The disclosure relates to methods for treating or inhibiting the growth of a tumor, wherein the methods include selecting a subject with a skin cancer and intralesionally administering to the tumor of the subject in need thereof a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor (e.g., an antibody or antigen-binding fragment thereof that specifically binds PD-1, PD-L1, and / or PD-L2). In certain embodiments, the skin cancer is cutaneous squamous cell carcinoma. In certain embodiments, the PD-1 inhibitor is administered into multiple locations of the tumor lesion.

Provided herein are recombinant antibodies, antigen-binding fragments, and fusion proteins thereof useful for binding to and inhibiting programmed death 1 (PD-1), nucleic acid molecules encoding the same and therapeutic compositions thereof, as well as methods of using such antibodies, including the methods for enhancing T cell and NK cell function to increase cell and cytokine mediated immunity and methods of treatment of various immune dysfunction related disorders including cancer and infectious diseases.

The disclosure relates to methods for treating or inhibiting the growth of a tumor, wherein the methods include selecting and administering to a subject in need thereof a therapeutically effective amount of an IL-4 / IL-13 pathway inhibitor and a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor. In certain embodiments, the IL-4 / IL-13 pathway inhibitor enhances the anti-tumor efficacy of PD-1 blockade.

To provide dosing regimens of an anti-TIGIT antibody useful for the treatment of cancer, in particular, dosing regimens in a combination therapy which comprises administering an anti-TIGIT antibody and an antibody of a Programmed Death 1 protein (PD-1) or Programmed Death Ligand 1 (PD-L1).SOLUTION: A method for treating cancer in a patient comprises administering, to a patient, 2.1 mg to 700 mg of an anti-TIGIT antibody comprising a heavy chain and a light chain, where the light chain comprises light chain CDRs of specific sequences and the heavy chain comprises heavy chain CDRs of specific sequences.SELECTED DRAWING: Figure 2A

Disclosed herein are recombinant antibodies specific to programmed death 1 (PD-1), chimeric antigen receptors (CARs) and genetically modified cells configured to express the CARs on their surfaces and secret the recombinant antibodies specific to PD-1. Also disclosed herein is a method of treating cancer by administering the genetically modified cells to a subject afflicted with cancer.

The disclosure relates to methods for treating or inhibiting the growth of a tumor, wherein the methods include selecting a subject with a skin cancer and intralesionally administering to the tumor of the subject in need thereof a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor (e.g., an antibody or antigen-binding fragment thereof that specifically binds PD-1, PD-L1, and / or PD-L2). In certain embodiments, the skin cancer is cutaneous squamous cell carcinoma. In certain embodiments, the PD-1 inhibitor is administered into multiple locations of the tumor lesion.

The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a VEGFR inhibitor, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1.

To provide PD-1 / PD-L1 pathway based disease treatment with antibodies that can effectively bind human PD-1 and block its binding with PD-L1 or PD-L2 to improve upon some of the challenges of existing therapies.SOLUTION: The present invention relates to an antibody or antigen-binding portion thereof that can bind to human programmed death 1 (PD-1). The antibody according to the present invention is further used in the preparation of a drug for treating disease in which expression of PD-1 is detrimental.SELECTED DRAWING: None

The present invention provides methods for treating, reducing the severity or inhibiting the growth of cancer (e.g., recurrent epithelioid sarcoma). The methods of the invention comprise administering to a subject in need thereof a therapeutically effective amount of a bispecific antibody that specifically binds mucoprotein 16 (MUC16) and CD3, either alone or in combination with a therapeutically effective amount of an antibody that specifically binds to the Programmed Death 1 (PD-1) receptor or an antigen-binding fragment thereof.

Isolated polypeptides are described, which are mutants of programmed death 1 ligand 2 (“PD-L2”) and can either activate or suppress immune cells through activating or suppressing programmed cell death protein 1 (“PD-1”). Also described are isolated polypeptides that block the activating or inhibitory site of PD-L2, thereby inhibiting or activating PD-1. Further described are pharmaceutical compositions including the polypeptides and methods of using the polypeptides.

The present disclosure provides methods for treating, reducing the severity, or inhibiting the growth of a MUC16-expressing cancer (e.g., ovarian cancer or endometrial cancer). In certain embodiments, the methods of the present disclosure comprise administering to a subject in need thereof a therapeutically effective amount of a bispecific antibody or antigen-binding fragment thereof that specifically binds mucin 16 (MUC16) and CD28 in combination with an antibody or antigen-binding fragment thereof that specifically binds to programmed death 1 (PD-1) receptor or a bispecific antibody or antigen-binding fragment thereof that specifically binds MUC16 and CD3.

The present disclosure describes a combination therapy comprising an antagonist of Programmed Death 1 receptor (PD-1), a lenvatinib or a pharmaceutically acceptable salt thereof, and (6S,9aS)-N- benzyl-8-({6-[3-(4-ethylpiperazin-l-yl)azetidin-l-yl]pyridin-2- yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-l- yl)hexahydro-2H-pyrazino[2,l-c][l,2,4]triazine-l(6H)-carboxamide (E7386) or a pharmaceutically acceptable salt thereof, and the use of the combination therapies for the treatment of a cancer.

Provided are canine antibodies (e.g., specific for canine programmed death 1) having improved yield and reduced antibody-dependent cell-mediated cytotoxicity effects in manufacturing processes. Also disclosed are nucleic acids encoding the antibodies, methods of treatment, and other methods or uses of the antibodies.

This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 as well as the interaction of CTLA4 with CD86 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.

This invention relates to combination therapies comprising a Programmed Death 1 receptor (PD-1) pathway inhibitor, and a Leukocyte Immunoglobulin Like Receptor B (LILRB) signaling inhibitor, and the use of the combination therapies for the treatment of cancer. The invention also relates to the treatment of cancer patients who are refractory to monotherapy with a PD-1 pathway inhibitor.

The present invention provides methods for treating, reducing the severity of, or inhibiting the growth of cancer (e.g., recurrent epithelioid sarcoma). The methods of the invention comprise administering to a subject in need thereof a therapeutically effective amount of a bispecific antibody that specifically binds to mucin 16 (MUC16) and CD3, alone or in combination with a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to the programmed death 1 (PD-1) receptor.

The present disclosure provides methods for treating, reducing the severity of, inhibiting the growth of a tumor, or inducing necrosis of a tumor, wherein the method includes selecting a patient with cancer (e.g., liver cancer, lung cancer, or head and neck cancer) in need thereof and administering to the patient a neoadjuvant therapy comprising a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor (e.g., cemiplimab or a bioequivalent thereof) in combination with radiation therapy (e.g., SBRT) or an anti-LAG-3 antibody (e.g., fianlimab) followed by surgical resection, and optional administration of a programmed death 1 (PD-1) inhibitor (e.g., cemiplimab or a bioequivalent thereof) as post-surgery adjuvant therapy. In certain embodiments, the cancer is liver cancer, such as hepatocellular carcinoma (HCC).

Provided herein are recombinant antibodies, antigen-binding fragments, and fusion proteins thereof useful for binding to and inhibiting programmed death 1 (PD-1), nucleic acid molecules encoding the same and therapeutic compositions thereof, as well as methods of using such antibodies, including the methods for enhancing T cell and NK cell function to increase cell and cytokine mediated immunity and methods of treatment of various immune dysfunction related disorders including cancer and infectious diseases.